Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Bifeprunox versus placebo for schizophrenia.

Chattopadhyay A, Frey S, Green G.

Cochrane Database Syst Rev. 2016 Oct 12;10:CD012029. Review.

PMID:
27732740
2.

Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis.

Wang B, Franklin JM, Eddings W, Landon J, Kesselheim AS.

PLoS One. 2016 Mar 31;11(3):e0152195. doi: 10.1371/journal.pone.0152195. eCollection 2016.

3.

Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.

Brown JW, Rueter LE, Zhang M.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Mar 3;49:53-62. doi: 10.1016/j.pnpbp.2013.11.008. Epub 2013 Nov 19.

PMID:
24269664
4.

Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.

Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.

Clin Ther. 2013 Dec;35(12):1867-75. doi: 10.1016/j.clinthera.2013.09.006. Epub 2013 Oct 8.

5.

Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs.

Schmidt RH, Jokinen JD, Massey VL, Falkner KC, Shi X, Yin X, Zhang X, Beier JI, Arteel GE.

J Pharmacol Exp Ther. 2013 Oct;347(1):126-35. doi: 10.1124/jpet.113.207621. Epub 2013 Aug 7.

6.

Sertindole: dilemmas for its use in clinical practice.

Pae CU.

Expert Opin Drug Saf. 2013 May;12(3):321-6. doi: 10.1517/14740338.2013.773971. Epub 2013 Feb 25.

PMID:
23432404
7.

Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.

Dusetzina SB, Cook BL, Busch AB, Alexander GC, Huskamp HA.

Psychiatr Serv. 2013 Jan;64(1):83-7. doi: 10.1176/appi.ps.201200002.

8.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
9.

Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory.

Dusetzina SB, Busch AB, Conti RM, Donohue JM, Alexander GC, Huskamp HA.

Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1251-60. doi: 10.1002/pds.3272. Epub 2012 May 3.

10.

Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC).

Geier JL, Karayal ON, Lewis M, Camm JA, Keane M, Kremer CM, Kolluri S, Reynolds R, Eng S, Strom BL.

Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1192-8. doi: 10.1002/pds.2185. Epub 2011 Jul 27.

PMID:
21796719
11.

Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].

McDonagh M, Peterson K, Carson S, Fu R, Thakurta S.

Portland (OR): Oregon Health & Science University; 2010 Jul.

12.

FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse.

Kuehn BM.

JAMA. 2009 Aug 26;302(8):833-4. doi: 10.1001/jama.2009.1152. No abstract available.

PMID:
19706851
13.

Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials.

Khan A, Schwartz K, Stern C, Redding N, Kolts RL, Brown WA, Robinson DS.

J Clin Psychiatry. 2007 Dec;68(12):1828-33.

PMID:
18162012
14.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators; Neurocognitive Working Group.

Arch Gen Psychiatry. 2007 Jun;64(6):633-47.

PMID:
17548746
15.

Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses.

Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC, Nolen WA.

J Clin Psychiatry. 2006 Jun;67(6):897-903. Review.

PMID:
16848649
16.

Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.

Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD.

Neuropsychopharmacology. 2007 Feb;32(2):284-8. Epub 2006 May 10.

17.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

18.

Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.

Woods SW, Gueorguieva RV, Baker CB, Makuch RW.

Arch Gen Psychiatry. 2005 Sep;62(9):961-70. Review.

PMID:
16143728
19.

Higher than Physician's Desk Reference (US) doses on atypical antipsychotics.

Goodnick PJ.

Expert Opin Drug Saf. 2005 Jul;4(4):653-68. Review.

PMID:
16011445
20.

Supplemental Content

Loading ...
Support Center